Canadian Pari-Mutuel Agency Industry Notifications

The following notifications describe the changes to the policy and legislation governing pari-mutuel betting and the Canadian Pari-Mutuel Agency's (CPMA) Equine Drug Control Program.

To receive Canadian Pari-Mutuel Agency email notifications or to unsubscribe from the distribution list send an email to aafc.cpmawebacpm.aac@agr.gc.ca.

Notifications

  • 2024

    The Canadian Pari-Mutuel Agency (CPMA) would like to remind trainers, owners, veterinarians and other stakeholders that the testing for the presence of capsaicin and isoflupredone continues under the Equine Drug Control Program.

    To minimize the risk of a positive test in their racehorse(s), the CPMA provides the following recommendations:

    Capsaicin

    Ensure that oral supplements or other oral products containing capsaicin are not administered or fed within 48 hours of a race.

    Do not feed cayenne pepper or other spices to a horse.

    Discontinue applications of topical products (for example ointments, liniments) that contain capsaicin within 48 hours of a race and review the ingredients list for any supplements given to racehorses for the presence of capsaicin.

    Isoflupredone

    A reminder that the new elimination guideline for a 10 mg IA / single dose of isoflupredone is 6 days. The intramuscular use is no longer recommended due to the variable and extended elimination of isoflupredone by this route.

    Any detection of capsaicin and isoflupredone outside these guidelines may result in a positive test.

    The CPMA strongly recommends consulting a veterinarian on any decision to administer supplements or medications to a racehorse.

    If you have any questions or concerns, please contact CPMA by telephone at 1-800-268-8835 or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

  • 2023

    Theobromine positives (September 7, 2023)

    Reminder: Authorized activities in the retention area while drug control services are active (July 28, 2023)

    Implementation of changes to the Canadian Pari-Mutuel Agency (CPMA) Elimination Guidelines with respect to isoflupredone (May 30, 2023)

    Addition of bupivacaine to the Schedule of prohibited drugs in the Regulations (May 10, 2023)

    Reminder on the use of supplements containing arsenic (April 26, 2023)

    Reminder: Implementation of Changes to the Canadian Pari-Mutuel Agency Elimination Guidelines (April 3, 2023)

    Changes to the Canadian Pari-Mutuel Agency Elimination Guidelines (March 7, 2023)

    Theobromine positives

    This memo is to update the racing industry regarding positive tests for theobromine.

    In the last few weeks, the Canadian Pari-Mutuel Agency (CPMA) has issued Certificates of Positive Analysis for theobromine and its metabolites from horses racing at some Canadian jurisdictions.

    Theobromine is commonly found in cacao beans and its byproducts left after processing. Numerous "positives" have been reported in other countries for theobromine, resulting from exposure of horses to small amounts of theobromine associated with cocoa pod husks in horse feeds.

    To assist horsepersons and minimize the risk of a positive test for theobromine in their racehorse(s), the CPMA provides the following recommendations:

    • Read product labels carefully to ensure that they do not contain cacao or cacao byproducts
    • Only feed horses supplements prescribed by a veterinarian and from reputable sources
    • Do not feed chocolate or cacao-based products
    • Do not let racehorses, their feed, supplements or equipment come into contact with food products containing chocolate

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

    Reminder: Authorized activities in the retention area while drug control services are active

    The Canadian Pari-Mutuel Agency (CPMA) is reminding race track employees, trainers, owners, veterinarians and other stakeholders that pursuant to the Pari-Mutuel Betting Supervision Regulations section 150(2) access to the retention area barn is limited to those involved directly with CPMA’s Equine Drug Control Program Collection Services and the horses chosen to undergo a test, along with their designated handlers. No other activities are allowed in the retention area while drug control services are active.

    Specifically, claimed race horses called to the retention area to undergo a test must be removed immediately after the sample collection has occurred. The claimed horse exchange must be undertaken after the horse has been released from the retention area.

    Implementation of changes to the Canadian Pari-Mutuel Agency (CPMA) Elimination Guidelines with respect to isoflupredone

    The CPMA would like to remind trainers, owners, veterinarians, and other stakeholders that the Elimination Guidelines (EG) for isoflupredone changed as of April 3, 2023. The change is detailed in the table below. Testing protocols for isoflupredone have been adjusted accordingly.

    Only the EGs currently published on the CPMA's website should be relied on when making treatment decisions for a racehorse.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a racehorse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

    Drug name Previous elimination guideline Current elimination guideline (effective April 3, 2023) Rationale for change
    Isoflupredone Intramuscular (IM)
    48h / 24 mg IM / single    		 Intra-articular (IA)
    6 days / 10 mg IA / single    		 The IM use is no longer recommended due to the variable and extended elimination of isoflupredone by this route.

    Addition of bupivacaine to the Schedule of prohibited drugs in the Regulations

    The Canadian Pari-Mutuel Agency (CPMA) has officially added bupivacaine to paragraph 1(d) of the Schedule to the Pari-Mutuel Betting Supervision Regulations. This drug was previously prohibited under paragraph 1(b) as a human drug.

    This change is due to the recent approval of a veterinary product containing bupivacaine by Health Canada.

    Bupivacaine is a local anesthetic similar to lidocaine and mepivacaine, and is used to block pain.

    Reminder on the use of supplements containing arsenic

    As the 2023 racing season is gearing up, the Canadian Pari-Mutuel Agency (CPMA) is reminding trainers, owners, veterinarians and other stakeholders that arsenic is considered a prohibited substance. Horsepersons should review the ingredients list for any supplements given to racehorses for the presence of arsenic. In order to help horsepersons identity if a product contains arsenic, they should look for words such as "sodium cacodylate" or "potassium arsenite" on the list of ingredients.

    The CPMA recommends discontinuing the use of all supplements containing arsenic at least 48 hours before a race.

    Reminder: Implementation of Changes to the Canadian Pari-Mutuel Agency Elimination Guidelines

    The Canadian Pari-Mutuel Agency (CPMA) is reminding the Canadian horse racing industry that changes to the Elimination Guidelines (EG) came into effect on April 3, 2023 and that the website and PDF have been updated. The urine and blood testing protocols have also been adjusted accordingly.

    All EGs remain the same except for those described in the Notice to Industry published on March 7, 2023.

    Only the EGs currently published on the CPMA's website should be relied on when making treatment decisions for a racehorse.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

    Changes to the Canadian Pari-Mutuel Agency Elimination Guidelines

    The Canadian Pari-Mutuel Agency (CPMA) is advising the Canadian horse racing industry of upcoming changes to the Elimination Guidelines (EG). Veterinarians and trainers should adjust their treatment protocols before the changes described below come into effect on April 3, 2023. The EGs on CPMA's website will be updated at that time.

    All EGs for medications not listed here will remain the same.

    Only the EGs currently published on the CPMA's website should be relied on when making treatment decisions for a racehorse.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

    Summary of upcoming changes to the EG

    Drug name Current elimination guideline New elimination guideline or change Rationale for change
    Atropine 24h / 15 mg IV / single 24h / 7 mg IV / single Reduced dose better reflects current prescribing recommendations.
    Ciclesonide New 48h / 2744 µg AER twice daily for 5 days, followed by 4116 µg AER once daily for 5 days Note that this EG applies to the Aservo Equihaler only, administered using the manufacturer's applicator.
    Dantrolene 36h / 1 g PO / single 48h / 1.5 g PO / single The EG was lengthened to allow for the larger single dose.
    Dembrexine
    • 72h / 150 mg PO / twice daily x 4 days
    • 72h / 150 mg PO / single
    • 72h / 150 mg PO / twice daily x 4 days
    • Removed
    		 Administrative change to simplify guidance.
    Dexamethasone
    • New
    • 48h / 25mg IV / single
    • 48h / 10mg PO / once daily x 5 days
    • 48h / 20 mg IM / single
    • 48h / 25mg IV / single
    • 48h / 10mg PO / once daily x 5 days
    		 The IM EG was developed in response to requests from veterinarians.
    Flunixin
    • 48h / 500 mg PO / single
    • 48h / 500 mg IV / single
    • 72h / 500 mg IM / single
    • 72h / 500 mg IM / once daily x 3 days
    • 72h / 500 mg IM / once daily x 5 days
    • 48h / 500 mg PO / single
    • 48h / 500 mg IV / single
    • Removed
    • Removed
    • Removed
    		 Intramuscular use is no longer recommended due to the risk of adverse reactions.
    Isoflupredone
    • 48h / 24 mg IM / single
    • New
    • Removed
    • 6 days / 10 mg IA / single
    		 The intramuscular use is no longer recommended due to the variable and extended elimination of isoflupredone by this route.
    Meloxicam
    • 48h / 90 mg PO / single
    • 54h / 270 mg IV / single
    • 72h / 250 mg PO / single
    • 72h / 270 mg IV / single
    		 The EG was lengthened to allow for the larger single oral dose.
    The IV dose was lengthened to be in line with other jurisdictions.
    Mepivacaine
    • 48h / 300 mg IA / single
    • 48h / 300 mg SC / single
    • 72h / 250 mg IA / single
    • 48h / 300 mg SC / single
    		 The dose was lowered to better represent the manufacturer's recommended IA dosage. The EG was lengthened to provide more time for re-evaluation of the horse between joint block and racing.
    Penicillin G Procaine
    • 425h / 2 million IU IM / single (Derapen, Diathol)
    • 425h / 4 million IU IM / single (Azimycin, Cillimycin, Penamycin, Pen-Strep Suspension, Pen Di Strep)
    • 425h / 4 million IU IM / once daily x 5 days (Pen Di Strep)
    • 425h / 6 million IU IM / single (Ethacillin)
    • 60h / 4 million IU PO / single
    • 48h / 0.2 million IU TOP / single
    • 425h / 2 million IU IM / single (Derapen, Diathol)
    • 425h / 4 million IU IM / single (Azimycin, Cillimycin, Penamycin, Pen-Strep Suspension, Pen Di Strep)
    • 425h / 4 million IU IM / once daily x 5 days (Pen Di Strep)
    • 425h / 6 million IU IM / single (Ethacillin)
    • Removed
    • Removed
    		 Penicillin G Procaine is no longer recommended for oral or topical use.
    Salicylic Acid
    • 24h / 11.7g PO / single
    • 6h / 8.38g TOP / single
    • 0h / 3.35g TOP / single
    • 24h / 11.7g PO / single
    • Removed
    • Removed
    		 The CPMA no longer supports the administration of this substance within 24 hours of racing.
    Theophylline
    • New
    • 96h / 1.5 g IV / single
    • 72h / 4 g PO / single
    • 96h / 1.5 g IV / single
    		 This EG was developed in response to requests from veterinarians.
    Triamcinolone acetonide
    • New
    • 6 days / 20 mg IA / single
    • 24h / 10 mg TOP / single
    • 6 days / 20 mg IA / single
    		 This EG was developed in response to requests from veterinarians.
    Trichlormethiazide
    • 24h / 100 mg PO / single
    • 24h / 200 mg PO / single
    • 24h / 100 mg IV / single
    • 36h / 100 mg IM / single
    • 48h / 100 mg PO / single
    • 48h / 200 mg PO / single
    • 48h / 100 mg IV / single
    • 48h / 100 mg IM / single
    		 The EG was changed to align with dexamethasone guidance.
    Xylazine 24h / 500 mg IV / single 48h / 500 mg IV / single The EG was lengthened to provide more time for re-evaluation of the horse between sedation and racing.
    Acronym Glossary
    ug Microgram
    AER Aerosol
    g Grams
    h Hours
    IA Intra-articular
    IM Intramuscular
    IU International Units
    IV Intravenous
    mg Milligrams
    PO Per os; by mouth; oral
    SC Subcutaneous Injection
    TOP Topical
  • 2022
     

    A reminder on the testing of arsenic, hydrocortisone and mirtazapine in official samples

    The Canadian Pari-Mutuel Agency (CPMA) would like to remind trainers, owners, veterinarians and other stakeholders that the testing of official samples for the presence Arsenic, Hydrocortisone and Mirtazapine started on August 1st, 2022 as indicated on the memo to the industry published on July 7, 2022.

    To minimize the risk of a positive test in their racehorse(s), the CPMA provides the following recommendations:

    Arsenic
    Considering horse and treatment variabilities, the use of arsenic containing supplements (including injectables) should be withdrawn for at least 48h before racing.

    The CPMA has adopted the international threshold of 300ng/mL in urine to control the use of arsenic in Canadian race horses.

    Hydrocortisone
    Synthetic hydrocortisone is being regulated through the detection of hydrocortisone esters in blood and urine.
    Elimination guidelines
    Solu-Cortef 250mg IV single – 48h
    Cortavance 152 µg TOP single – 24h

    Mirtazapine
    It is an antidepressant used to treat a wide range of conditions, from behavioral problems to loss of appetite in cats. No elimination guideline is available.

    Any detection of mirtazapine, hydrocortisone esters or amounts of arsenic above 300ng/mL (urine) may result in a positive test.

    The CPMA strongly recommends consulting a veterinarian on any decision to administer supplements or medications to a racehorse.

    Addition of arsenic, hydrocortisone, and mirtazapine to the Schedule of prohibited drugs in the Regulations and clarification of prohibitions regarding zilpaterol hydrochloride

    The Canadian Pari-Mutuel Agency (CPMA) has made the following changes to the Schedule to the Pari-Mutuel Betting Supervision Regulations; Arsenic, Hydrocortisone and Mirtazapine are added to the list, and the current restriction for zilpaterol hydrochloride is broadened to include all zilpaterol preparations.

    Arsenic is considered a performance-altering substance with considerable gastrointestinal toxic effects. Because arsenic is naturally occurring in the environment, horse urine contains low levels of arsenic. This amendment will add arsenic to section 2 of the Schedule, and adopt the international threshold of 300ng/mL in urine to control the use of arsenic in Canadian race horses. The CPMA recommends discontinuing the use of all supplements containing arsenic at least 48 hours before a race.

    Hydrocortisone is a potent steroidal anti-inflammatory. It is used to treat allergies and other inflammatory conditions. It will be added to section 1 of the Schedule. Synthetic hydrocortisone will be regulated through the detection of hydrocortisone esters in blood and urine.

    No. horses Product Dose /Route Administration EG
    4 Solu-Cortef 250 mg IV single 48 h
    4 Cortavance 152 µg TOP single 24 h

    Mirtazapine is an antidepressant used to treat a wide range of conditions, from behavioral problems to loss of appetite in cats. The addition of this substance to section 1 of the Schedule is consistent with the current approach for other antidepressants.

    Zilpaterol hydrochloride is currently listed in section 1 of the Schedule. This amendment will remove the word "hydrochloride", and clarify that any zilpaterol preparation, metabolite, derivative, isomer and salt should not be present in the sample.

    Any detection of the above drugs may result in a positive test.

    The CPMA strongly recommends consulting a veterinarian on any decision to administer supplements or medications to a racehorse.

    Testing for these drugs will begin on August 1st, 2022.

    A Reminder on the Recommendations on Reducing the Risk of a Positive Test in Racehorses

    As the 2022 racing season is gearing up, the Canadian Pari-Mutuel Agency (CPMA) is reminding trainers, owners,   veterinarians and other stakeholders of the following recommendations  to assist them in minimizing the risk of a positive test in their racehorse(s):

    Human prescription medications and/or non-prescription supplements

    • Do not let racehorses, their feed, supplements or equipment come into contact with human medications or supplements.
    • Prohibit people from urinating or spitting in stalls.
    • Ensure that people wash their hands immediately after touching or taking medications, and before touching a racehorse or associated equipment.

    Bedding

    • Ensure that tulip poplar and related wood is not used when bedding horses on shavings. This may result in a glaucine positive test. The use of 100% pine shavings is a safer choice.

    Compounded medications, supplements and other natural products

    • Do not apply the CPMA's Elimination Guidelines to compounded medications because their elimination from the horse may be different from that of an approved veterinary medication.
    • Only feed horses supplements prescribed by a veterinarian.
    • Read labels carefully to ensure that products do not contain prohibited substances.

    Cobalt salts & vitamin B12

    • Discontinue all supplements at least 48 hours before a race. This will reduce but not eliminate the risk of a positive test result.
    • Keep in mind that longer withdrawal times may be required for horses that have received repeated doses of cobalt-containing supplements and vitamin B12 because cobalt levels can build up, resulting in elevated levels for prolonged periods of time.
    • Cease any use of multiple supplements containing cobalt or vitamin B12.

    Cannabis

    • Do not use supplements or products derived from cannabis (for example CBD oil and supplements, hemp oil) on horses.
    • Do not use or allow cannabis products around horses.
    • Wash hands immediately after touching or taking cannabis products and before touching a racehorse or associated equipment.

    Capsaicin

    • Ensure that oral supplements or other oral products containing capsaicin are not administered or fed at least 48 hours before a race. This will reduce but not eliminate the risk of a positive test result.
    • Do not feed cayenne pepper or other spices to a horse.
    • Discontinue applications of topical products (for example ointments, liniments) that contain capsaicin at least 48 hours before a race.

    The CPMA strongly recommends that you

    • Consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca

     

    Delayed implementation of the new edition of the CPMA Elimination Guidelines

    After further consideration, the Canadian Pari-Mutuel Agency (CPMA) would like to advise the Canadian horseracing industry that the implementation of the new edition of the CPMA Elimination Guidelines, as announced February 7th 2022 ("Changes to the CPMA Elimination Guidelines"), will be delayed until further notice.

    The CPMA will be undertaking additional discussions regarding some of the proposed changes.

    Should you have any questions or concerns regarding the above or any other pari-mutuel betting matter, please do not hesitate to contact the CPMA by telephone at 1-800-268-8835, or by Email at aafc.cpmawebacpm.aac@agr.gc.ca.

  • 2021
     

    Recommendations on reducing the risk of a positive test in racehorses (March 23, 2021)

    The Canadian Pari-Mutuel Agency (CPMA) provides the following recommendations to assist horsepersons and minimize the risk of a positive test in their racehorse(s).

    Human prescription medications and/or non-prescription supplements

    • Do not let racehorses, their feed, supplements or equipment come into contact with human medications or supplements.
    • Prohibit people from urinating or spitting in stalls.
    • Ensure that people wash their hands immediately after touching or taking medications, and before touching a racehorse or associated equipment.

    Bedding

    • Ensure that tulip poplar and related wood is not used when bedding horses on shavings. This may result in a glaucine positive test. The use of 100% pine shavings is a safer choice.

    Compounded medications, supplements and other natural products

    • Do not apply the CPMA's Elimination Guidelines to compounded medications because their elimination from the horse may be different from that of an approved veterinary medication.
    • Only feed horses supplements prescribed by a veterinarian.

    Cobalt salts & vitamin B12

    • Discontinue all supplements within 48 hours of the race. This will reduce but not eliminate the risk of a positive test result.
    • Keep in mind that longer withdrawal times may be required for horses that have received repeated doses of cobalt-containing supplements and vitamin B12 because cobalt levels can build up, resulting in elevated levels for prolonged periods of time.
    • Cease any use of multiple supplements containing cobalt or vitamin B12.

    Cannabis

    • Do not use supplements or products derived from cannabis (for example, CBD supplements, hemp oil) on horses.
    • Do not use or allow cannabis products around horses.
    • Wash hands immediately after touching or taking cannabis products and before touching a racehorse or associated equipment.

    Capsaicin

    • Ensure that oral supplements or other oral products containing capsaicin are not administered or fed within 48 hours of a race.
    • Do not feed cayenne pepper or other spices to a horse.
    • Discontinue applications of topical products (for example ointments, liniments) that contain capsaicin within 48 hours of a race.

    The CPMA strongly recommends that you:

    • consult your veterinarian on any decision to administer supplements or medications to a horse
    • subscribe to receive Canadian Pari-Mutuel Agency email notifications: Email Subscription Service

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Change to retention area procedure (March 8, 2021)

    The Canadian Pari-Mutuel Agency (CPMA) is advising the Canadian horseracing industry that as of April 1, 2021, when a Test Inspector (TI) takes control of a horse in the retention area, they will ask the horse handler if they are aware of their rights to witness the sample collection, sealing and identification, rather than reading them those rights. If the person replies that they are not aware, the TI will refer them to a poster that is prominently displayed that describes those rights. The TI will also answer any questions the handler may have.

    There are no changes to the Pari-Mutuel Betting Supervision Regulations or to a sample witness' rights. The owner or trainer of a horse chosen to undergo a test, or their representative, may continue to:

    1. witness the collection of the official sample
    2. witness the sealing and identification of the official sample container
    3. sign the documentation that accompanies the official sample

    With respect to paragraph (c) above, horsepersons will continue to provide their name and license number to the Test Inspector in lieu of a signature as witness to the sample collection.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

  • 2020
     

    Medroxyprogesterone Advisory (December 1, 2020)

    The Canadian Pari-Mutuel Agency (CPMA) is advising veterinarians and race-horse trainers and owners that medroxyprogesterone is a prohibited substance in Canada because its use has been associated with deaths in horses and approved veterinary products containing this substance are not available in Canada. In addition, there is published information supporting its lack of efficacy in suppressing estrus, its main reason for use.

    Products containing medroxyprogesterone should not be administered to a race-horse for any reason.

    Medroxyprogesterone can be detected in post-race samples for an extended period of time, and may result in a positive test.

    Testing for medroxyprogesterone will begin on June 1, 2021.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Addition of Amlodipine, Ciclesonide and Methadone to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations (November 2, 2020)

    In consultation with its Drug Advisory Committee, the Canadian Pari-Mutuel Agency (CPMA) has officially added the following drugs to section 1 of the Schedule to the Pari-Mutuel Betting Supervision Regulations: Amlodipine, Ciclesonide and Methadone.

    • Amlodipine is an approved veterinary drug used to reduce high blood pressure in cats. This drug is not recognized for use in horses.
    • Ciclesonide is an inhaled steroid used to treat breathing problems in horses caused by asthma. The CPMA intends to develop and publish an Elimination Guideline for ciclesonide.
    • Methadone is an opioid painkiller licensed for cats.

    Any detection of the above drugs may result in a positive test.

    The CPMA strongly recommends consulting a veterinarian on any decision to administer supplements or medications to a racehorse.

    Testing for these drugs will begin on December 1, 2020.

     

    Capsaicin Update (October 6, 2020)

    This memo is to update the racing industry regarding the positive tests for capsaicin.

    Since June 2020, the Canadian Pari-Mutuel Agency (CPMA) has issued Certificates of Positive Analysis for capsaicin in all Canadian jurisdictions that raced.

    When a cluster of positive cases is reported, the CPMA begins an investigation, in collaboration with the provincial regulatory bodies (PRB), to determine the source of the positive cases.

    Investigations by PRB have revealed multiple possible sources for the positive tests, including trainers feeding cayenne pepper and capsaicin-contaminated supplements. However, the use of anti-chewing and cribbing products poses a low risk of causing a positive test for capsaicin.

    PRB investigations have also revealed the undeclared presence of capsaicin in various regulated and unregulated supplements. Therefore, the CPMA has adjusted its testing criteria for capsaicin to reduce the likelihood that these products will cause a positive test result.

    Nevertheless, the administration of oral supplements and/or topical preparations containing capsaicin within 24h of a race may still cause a positive test result. To reduce the risk of a positive test, all oral supplements and topical products should be withdrawn at least 48h before a race.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Capsaicin Frequently Asked Questions (July 16, 2020)

    Subsequent to its memo published June 23, 2020, the Canadian Pari-Mutuel Agency (CPMA) received questions regarding the use of capsaicin-containing products in racehorses and their environment. The purpose of this memo is to provide answers to the most frequently asked questions.

    1. When did capsaicin become a prohibited substance?
    Capsaicin has always been a prohibited substance in CPMA official blood and urine samples. The CPMA's September 2019 and June 2020 memos were not advisories about a change in the regulatory status for capsaicin but reminders to the industry of its prohibited status.
    2. Did CPMA recently change its capsaicin testing protocol without informing the industry?
    The CPMA has not changed its testing protocol for capsaicin.
    3. Why isn't capsaicin in the Elimination Guidelines?
    The CPMA provides Elimination Guidelines for some therapeutic products that have been approved by Health Canada. There are no currently approved products that have been issued a Drug Identification Number (DIN) and contain only capsaicin.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements, medications or other products to a horse.

    If you have any questions or concerns, please contact CPMA by telephone at 1-800-268-8835 or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Capsaicin Advisory (June 23, 2020)

    This memo is further to the Canadian Pari-Mutuel Agency's (CPMA) notice to industry on September 19, 2019 on the subject of capsaicin, and reminds veterinarians, racehorse trainers and owners that capsaicin is a prohibited substance in Canada due to its painkilling properties.

    Capsaicin is an extract from chili peppers (for example, cayenne) that can be found in topical creams available over-the-counter in pharmacies. It is also sometimes applied to bandages and to stall walls to discourage chewing.

    Products containing capsaicin should not be administered to a racehorse as they may trigger a positive test.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions or concerns, please contact CPMA by telephone at 1-800-268-8835 or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Return to racing – retention area requirements for associations and horsepersons (May 19, 2020)

    In preparation for a return to racing, the Canadian Pari-Mutuel Agency (CPMA) is advising the industry of requirements that will be in place for the retention area while public health mitigation measures related to COVID-19 (SARS-CoV-2) are active.

    All requirements take into account the need to minimize the number of horses in the retention area at any one time, and prioritize physical distancing and personal protection between people.

    The wearing of masks and gloves at all times while in the retention area is mandatory.

    Racetracks must assign a person to control access to the retention area and to hand out masks and gloves.

    Changes to usual procedures:

    • A maximum of two people may enter the retention area with a horse called to test.
    • Every effort must be made to keep at least 2m (6ft) between people at all times.
    • Horses must be attended by at least one horseperson at all times.
    • Retention time will be reduced to 40 minutes (from 60 minutes).
    • Horsepersons are requested to keep cooling out and bathing time to a minimum.
    • Horsepersons should only touch their own horse and equipment, and may touch wash stall cross-ties, hoses and faucets. Retention area staff will open and close all doors as needed.
    • Horsepersons will provide their name and license number to the Test Inspector in lieu of a signature as witness to the sample collection.
    • Horsepersons may not enter the stall with the Test Inspector and horse unless specifically requested by the Test Inspector. They may witness sample collection via the peephole if the stall door is closed.
    • Horsepersons may not enter the office and/or sample processing areas. They may witness sample processing from designated areas.
    • Horsepersons must stand on the opposite side of the horse from the Test Inspector during blood collections.

    For questions or concerns, please contact the CPMA at 1-800-268-8835 or aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Changes to CPMA Elimination Guidelines including changes to clenbuterol testing (April 3, 2020)

    The Canadian Pari-Mutuel Agency (CPMA) announces that, effective immediately, the Elimination Guidelines have been updated and will now be ONLY AVAILABLE online.

    Moving forward, the Elimination Guidelines will be updated on an "as needed" basis. For each future update, the CPMA will send out an Industry Notice to those subscribed to the Email Subscription Service.

    The printed Elimination Guidelines booklet is now obsolete. Changes in this new online edition include changes to clenbuterol testing as well as the addition of five new drugs, as described below:

    1. Guidance for clenbuterol use has been extended from 7 days to 28 days. The new testing will be effective on May 1, 2020.
    2. Addition of new guidelines for the following five drugs:
      • Cetirizine (for example Reactine)
      • Clodronate (for example Osphos)
      • Fluticasone (for example Flovent)
      • Fluticasone / Salmeterol (for example Advair)
      • Ipratropium bromide (for example Atrovent)

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer any supplement or medication to a racehorse.

    If you have any questions, please contact the CPMA at 1-800-268-8835 or at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Addition of Altrenogest, Grapiprant, and Lubabegron to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations (March 18, 2020)

    In consultation with its Drug Advisory Committee, the Canadian Pari-Mutuel Agency (CPMA) has officially added the following drugs to section 1 of the Schedule to the Pari-Mutuel Betting Supervision Regulations: Altrenogest, Grapiprant and Lubabegron.

    • Altrenogest is an oral hormone that is used to keep female horses from coming into heat, and to suppress unwanted behaviours associated with heat cycles. It is also used to modify behaviour in male horses. Use in females is a legitimate therapeutic use. Use in males is not, and this use is prohibited by many jurisdictions internationally. In alignment with other jurisdictions, and through a policy decision, the CPMA will only prohibit this drug's use in male horses. Veterinarians and trainers may continue to use Altrenogest in female horses.
    • Grapiprant is a drug used to treat arthritis pain and inflammation in dogs. This drug is not recognized for use in horses.
    • Lubabegron is a drug used in cattle to reduce ammonia gas emissions. This drug is not recognized for use in horses.

    Therefore, any detection of the above drugs, with the exception of Altrenogest in female horses, may result in a positive test.

    The CPMA strongly recommends consulting a veterinarian on any decision to administer supplements or medications to a racehorse.

    Testing for these drugs will begin on May 1, 2020.

     
  • 2019
     

    Capsaicin Advisory (September 19, 2019)

    The Canadian Pari-Mutuel Agency (CPMA) is advising veterinarians and racehorse trainers and owners that capsaicin is a prohibited substance in Canada due to its painkilling properties. Veterinary products containing capsaicin are not approved for use in Canada. Products containing capsaicin should not be administered to a racehorse.

    Capsaicin is an extract from chili peppers that can be found in topical creams available over-the-counter in pharmacies.

    Capsaicin can be detected in official samples, and may result in a positive test.

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer supplements or medications to a horse.

    If you have any questions or concerns, please contact CPMA by telephone at 1-800-268-8835 or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Cannabis and Equine Drug Control (July 29, 2019)

    The Canadian Pari-Mutuel Agency (CPMA) is reminding those that care for or have control of racehorses in Canada that any cannabis use in racehorses continues to be prohibited.

    This includes the use of two primary chemicals found in cannabis: tetrahydrocannabinol (THC) and cannabidiol (CBD).

    Although cannabis is permitted for restricted use in humans, there are currently no veterinary cannabis products approved by Health Canada. Therefore, using a product (for example, CBD supplements, hemp) containing either of these chemicals may result in a positive drug test.

    Due to the absence of Health Canada approved veterinary cannabis products and the wide variety in CBD supplements marketed for horses, providing elimination guidance for cannabis products is not possible.

    People that use cannabis and care for or have control of racehorses in Canada should take steps to guard against potential contamination of the horses (for example, keep cannabis out of a horse's reach, wash hands after touching cannabis products).

    The CPMA strongly recommends that you consult your veterinarian on any decision to administer any supplement or medication to a racehorse.

    If you have any questions or concerns, please contact CPMA by telephone at 1-800-268-8835 or by Email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Delayed implementation of the new edition of the CPMA Elimination Guidelines (March 18, 2019)

    The Canadian Pari-Mutuel Agency (CPMA) would like to advise the Canadian horseracing industry that the implementation of the new edition of the CPMA Elimination Guidelines, as announced February 18th 2019 ("New edition of the CPMA Elimination Guidelines"), will be delayed until further notice.

    The CPMA will be engaging industry stakeholders regarding some of the proposed changes.

    Should you have any questions or concerns regarding the above or any other pari-mutuel betting matter, please do not hesitate to contact the CPMA by telephone at 1-800-268-8835, or by Email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    New edition of the CPMA Elimination Guidelines (February 18, 2019)

    The Canadian Pari-Mutuel Agency (CPMA) is pleased to advise the Canadian horseracing industry that a new edition of the CPMA Elimination Guidelines will be published in March 2019.

    The new elimination guidelines will come into force on April 1, 2019.

    The following is a summary of the changes, sorted into five categories:

    1. Substances completely removed from the guidelines:
      • These substances have been removed because no Health Canada approved product is available or veterinary use of the substance is no longer recommended
      • These substances remain prohibited under the Pari-Mutuel Betting Supervision Regulations
      • Testing of official samples for the presence of these substances will continue;
      • Guidance on elimination will no longer be provided
      • Use of any of these substances, including in compounded form, may result in a positive test.
      • Acetaminophen
      • Aminocaproic acid
      • Carbazochrome
      • Chloroprocaine
      • Chloropheniramine
      • Chlorpromazine
      • Cromoglycate
      • Diflunisal
      • Dyphylline
      • Ergonovine
      • Ethacrynic acid
      • Etodolac
      • Fenoterol
      • Floctafenine
      • Flurbiprofen
      • Ibuprofen
      • Indapamide
      • Indomethacin
      • Meclofenamic acid
      • Mefenamic acid
      • Nedocromil
      • Oxaprozin
      • Pentazocine
      • Pentoxifylline
      • Phenothiazine
      • Piroxicam
      • Reserpine
      • Salmeterol
      • Sulindac
      • Tenoxicam
      • Tiaprofenic acid
      • Tripelennamine
      • Vedaprofen
      • Zompirac
    2. Substances with some doses and routes of administration removed from the guidelines:
      • Testing of official samples for the presence of these substances will be based only on the doses and routes included in the guidelines
      • No elimination guidelines will be provided for doses and routes contained in previous editions of the guidelines
      • Use of doses and routes for any of the substances that are not included in the guidelines may result in a positive test.
      Drug Change
      Dembrexine Removal of guidance for single administration
      Diclofenac Removal of guidance for oral use
      Ephedrine Removal of guidance for 300 mg oral dose
      Flunixin Removal of guidance for oral and intramuscular use
      Guaifenesin Removal of guidance for oral use
      Hydrochlorothiazide Removal of guidance for intravenous use
      Hyocine butylbromide Removal of guidance for oral use
      Mepivacaine Removal of guidance for intra-articular use
      Penicillin G procaine Removal of guidance for oral and topical uses
      Phenylbutazone Removal of guidance for 3 g oral regimen and both 3 g IV doses
      Salicylic acid Removal of guidance for 3.35 g and 8.38 g topical doses
      Trichlormethiazide Removal of guidance for intravenous use
    3. Substances with modified elimination guidelines (some doses and routes):
      • Testing of official samples for the presence of these substances will be based on the elimination guidelines included in the new edition of the guidelines
      • Use of any of these substances outside the published elimination guidelines may result in a positive test.
      Drug Change
      Clenbuterol Elimination guidance extended from 7 days to 21 days
      Dantrolene Increase from 1g oral/single dose/36 h to 1.5 g oral/single dose/48 hours
      Isoflupredone Decrease intramuscular dose from 24 mg to 20 mg
      Phenylbutazone Elimination guidance for 2 g doses extended from 48 hours to 96 hours
      Pyrilamine Elimination guidance for 750 mg oral dose extended from 36 hours to 48 hours
      Triamcinolone acetonide Elimination guidance for intra-articular use extended from 6 days to 10 days
      Trichlormethiazide Elimination guidance for oral and intramuscular doses all extended to 48 hours
    4. Substances added to the 2019 edition of the guidelines:
      Drug Change
      Cetirizine[1] 200 mg oral/single dose/72 hours
      Clodronate[2] 720 mg intramuscular/single dose/30 days
      Fluticasone 2 mg aerosol/twice daily for 7 days/24 hours
      Fluticasone/Salmeterol 2.5 mg & 250 µg aerosol/twice daily for 7 days/24 hours
      Ipratropium bromide 0.18 mg aerosol/once daily for 3 days/24 hours

      [1] Note that concurrent administration of cetirizine and oral ivermectin will significantly increase the elimination time of cetirizine.

      [2] Applies to horses 4 years of age and older. For more details, see CPMA Industry Notification dated May 31, 2018, "Addition of clodronate and tiludronate to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations."
    5. Substances with some doses and routes added to the 2019 edition of the guidelines:
      Drug Change
      Dexamethasone 20 mg intramuscular/single dose/48 hours
      Isoflupredone 10 mg intra-articular/single dose/ 6 days
      Triamcinolone acetonide 10 mg topical/single dose/24 hours
      Triamcinolone acetonide 10 mg intramuscular/single dose/10 days

      The CPMA strongly recommends that your veterinarian be consulted on any decision to administer any supplement or medication to a horse.
      To order booklet copies of the Elimination Guidelines 2019 or should you have any questions or concerns regarding the above or any other pari-mutuel betting matter, please do not hesitate to contact the CPMA by telephone at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     
  • 2018
     

    Calculation of the 100 day Exercise-Induced Pulmonary Hemorrhage list requirement (October 30, 2018)

    The Canadian Pari-Mutuel Agency (CPMA) has received an inquiry concerning the requirement for a horse to remain on a provincial Exercise-Induced Pulmonary Hemorrhage (EIPH) list for 100 days, when the horse moves from one EIPH list to a new province's EIPH list.

    The Pari-Mutuel Betting Supervision Regulations (the Regulations) require provincial Commissions to maintain an up-to-date list of horses that participate in their EIPH program. Any horse on a province's EIPH list is required to remain on that list for a period of at least 100 days.

    Where the horse comes from another Canadian province, the 100 days may be counted from the date the horse was most recently added to the EIPH list, assuming the date can be confirmed by that originating provincial Commission (for example, if 40 days have passed on the original list then the horse must remain on the new list for another 60 days). Where the exact start date on that EIPH list cannot be confirmed by the originating Commission, or, if the horse arrived from outside Canada, the start date is the first day the horse is added to the new province's EIPH list (for example, day 1 of 100).

    Should you have any questions or concerns regarding the above or any other pari-mutuel betting matter, please do not hesitate to contact CPMA by telephone at 1-800-268-8835, or by Email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Levamisole reminder (October 30, 2018)

    The Canadian Pari-Mutuel Agency (CPMA) is reminding veterinarians and race-horse trainers and owners that levamisole is a prohibited substance in Canada because it metabolizes into aminorex, a prohibited stimulant. Levamisole should not be administered to a race-horse for any reason.

    Levamisole can be detected in post-race samples for a long period of time, and may result in a positive test weeks after an administration.

    The CPMA strongly recommends that your veterinarian be consulted on any decision to administer any supplement or medication to a horse.

    Should you have any questions or concerns regarding the above or any other pari-mutuel betting matter, please do not hesitate to contact CPMA by telephone at 1-800-268-8835, or by Email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Addendum to the CPMA 2016 Elimination Guidelines Booklet (August 1, 1018)

    The Canadian Pari-Mutuel Agency (CPMA) is pleased to provide the Canadian horse racing industry with the following new elimination guidelines. The information published in the 2016 Elimination Guidelines book continues to be valid. There is no date for publication of a new edition of the book.

    Dosage Regimen and Elimination Guideline (EG)
    # Horses Drug Product Dose/route Administration Elimination guideline (EG)
    4 Cetirizine1 Reactine 200 mg PO Single 72 hours
    5 Clodronate2 Osphos 720 mg IM Single 30 days
    4 Dexamethasone Dexamethasone5 20 mg IM Single 48 hours
    5 Fluticasone Flovent 2 mg AER Twice daily for 7 days 24 hours
    5 Triamcinolone acetonide Viaderm KC 10 mg TOP Single 24 hours

    1 Note that concurrent administration of cetirizine and oral ivermectin will significantly increase the elimination time of cetirizine.

    2 Applies to horses 4 years of age and older. For more details, see CPMA Industry Notification dated May 31, 2018, "Addition of clodronate and tiludronate to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations."
    AER
    Aerosol
    EG
    Elimination Guidelines
    IA
    Intra-articular
    IM
    Intramuscular
    PO
    Per os (oral)
    TOP
    Topical

    It is stressed that these results are presented as guidelines only and should not be construed as absolute for every horse to which this drug is administered.

    The guidelines in this notice should not be applied to a compounded product and may not be consistent with foreign regulations and laboratory methods.

    As always, the CPMA strongly recommends that your veterinarian be consulted on any decision to administer any supplement or product to a horse.

    Should you have any questions or concerns regarding this matter, please do not hesitate to contact CPMA at aafc.cpmawebacpm.aac@agr.gc.ca or by calling 1-800-268-8835.

     

    Changes in management at the Canadian Pari-Mutuel Agency (June 20, 2018)

    After almost 12 years at the Canadian Pari-Mutuel Agency (CPMA) and almost 7 years as its Executive Director, it is with mixed emotions that I advise industry and stakeholders, many of whom have become friends that I have decided to retire at the end of June.

    Tim Walker, currently the CPMA's Associate Executive Director, will act in the position of Executive Director from June 30th until October 26th and Dr. Carolyn Cooper, currently Director of the CPMA's Equine Drug Control Program, will act in the position from October 29th until February 28th, 2019. During that time a competitive process will be run to fill the position on a permanent basis.

    Since arriving at the CPMA, I have seen both the Agency and the industry go through significant changes. This has necessitated that we evaluate the CPMA on an ongoing basis, to focus on our core mandate, review our programs and services, and the overall effectiveness of how we do business. We have made several changes to the Pari-Mutuel Betting Supervision Regulations (the Regulations) to reduce the regulatory and administrative burden on racetrack associations in obtaining betting permits, licences and other approvals. We have also made it much simpler and quicker for associations to add new betting products and make changes to existing ones. We have become more open and transparent, particularly in the area of equine drug control, so that those in the industry better understand what we do, why we do it and how.

    Financially, the CPMA went through some challenging times and, as the industry changed and the federal levy on pari-mutuel betting on horse racing decreased, the CPMA has had to adjust accordingly. As a result, we are currently in a favourable financial position that should carry us through the next 3-5 years which will allow the new management regime to plan for the Agency's longer term direction.

    Finally, I'd like to say that we have an amazing group of people in this industry. Over the years, I have been continually impressed by the passion and dedication of everyone involved in this great sport. Not having had a background in horse racing or betting when I first arrived, I have leaned on many knowledgeable people to better understand the industry – too many to name individually but you know who you are – and I thank you for that support.

    I wish you all the best of luck in the future.

    Steve Suttie

     

    Addition of clodronate and tiludronate to the Schedule of Prohibited Drugs in the Pari-Mutuel Betting Supervision Regulations (May 31, 2018)

    Please be advised that the regulatory amendment to add the drugs clodronate and tiludronate to the Schedule to the Pari-Mutuel Betting Supervision Regulations.

    Clodronate and tiludronate belong to a class of drugs known as bisphosphonates. These drugs are licensed in Canada by Health Canada for the treatment of navicular disease in horses. Additionally, the drugs have anti-inflammatory and pain relieving effects.

    Due to the drugs' effects on bone, as well as their ability to reduce pain, the Canadian Pari-Mutuel Agency (CPMA), in consultation with its Drug Advisory Committee, has determined that these drugs should be added to the list of prohibited drugs in the Schedule to the Pari-Mutuel Betting Supervision Regulations.

    The CPMA recognizes the importance of these drugs in the treatment of lameness, and so has set an Elimination Guideline of 30 days for horses 4 years of age and older, which aligns with withdrawal periods previously set for these drugs by the British Horseracing Authority and the International Equestrian Federation (FEI).

    The use of clodronate or tiludronate in a 2 or 3 year old horse is prohibited and any confirmed presence will result in a positive test.

    No. of horses Product Dose, Route Admin EG
    5 OSPHOS 720 mg, IM Single 30 days
     

    Testing for these drugs will begin on August 1, 2018.

     

    Notice to industry regarding cobalt – follow up (May 9, 2018)

    The Canadian Pari-Mutuel Agency (CPMA) would like to provide the Canadian horse racing industry with an update on cobalt testing since it was transferred from the provincial racing commissions in April 2017.

    In the past 12 months, the CPMA has issued seven Certificates of Positive Analysis for cobalt; all were in urine. Cobalt concentrations for positive tests ranged from 116 ng/mL to 340 ng/mL. For reference, the regulatory thresholds are 100 ng/mL in urine and 25 ng/mL in blood.

    In order to avoid a positive test, the International Federation of Horseracing Authorities recommends that no more than 1 mg of cobalt per injected dose or no more than 5 mg of cobalt per oral dose be given to a horse. The CPMA agrees with this advice, and also recommends that all supplements containing cobalt be withheld for the 48 hours preceding a race.

    As always, the CPMA strongly recommends that your veterinarian be consulted on any decision to administer any supplement or product to a horse.

    Should you have any questions or concerns regarding this matter, please do not hesitate to contact CPMA at aafc.cpmawebacpm.aac@agr.gc.ca or by calling 1-800-268-8835.

     

    CPMA Policy Paper P-011, Foreign currency exchange rates - Effective May 1, 2018

    Please be advised of the Canadian Pari-Mutuel Agency (CPMA) issuance of Policy Paper P-011 respecting "Foreign Currency Exchange Rates".

    This paper will provide additional direction for applying the currency exchange rules under subsection 51(4) of the Pari-Mutuel Betting Supervision Regulations.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

  • 2017
     

    Glaucine (July 6, 2017)

    The Canadian Pari-Mutuel Agency (CPMA) would like to let horsepersons in Canada know that although glaucine continues to be classified as prohibited substance under the Pari-Mutuel Betting Supervision Regulations, the CPMA has taken steps to differentiate glaucine abuse from environmental exposure.

    Glaucine is a natural substance produced by several species of plants, including the tulip poplar tree (Liriodendron tulipifera), which is native to eastern North America. While glaucine has also been recognized as a cough suppressant and an anti-inflammatory that is a weak painkiller, it is not approved for use by Health Canada in humans or animals. Glaucine is prohibited by many horse racing jurisdictions, including by the CPMA, because it is not an approved medication and because of its potential for abuse.

    Subsequent to positive tests for glaucine in the United States that were later linked to environmental exposure, horsepersons have expressed concern that a similar situation could arise in Canada. In order to prevent this type of situation, the CPMA has adjusted its testing protocols for glaucine.

    There are steps, however, that horsepersons can take to reduce or eliminate their horse's environmental exposure to glaucine. The CPMA recommends working with suppliers of wood shavings to ensure that material is not sourced from tulip poplar trees or other glaucine-producing plants. In addition, do not administer any products to your horse that may contain glaucine.

    Should you have any questions or concerns regarding this matter, please do not hesitate to contact CPMA at aafc.cpmawebacpm.aac@agr.gc.ca or by calling 1-800-268-8835.

     

    Approval of a proposal by the Central Ontario Standardbred Association to stock clean towels in the retention area at Mohawk Raceway and Woodbine Racetrack (Harness) (June 15, 2017)

    The Canadian Pari-Mutuel Agency (CPMA) has approved a pilot project proposed by the Central Ontario Standardbred Association (COSA) whereby clean towels will be made available for horseperson's use within the retention areas at Mohawk Raceway and Woodbine Racetrack (Harness).

    This pilot program is a joint undertaking between COSA and the Woodbine Entertainment Group, the race-course association responsible for the operation of the retention areas at both race-course locations. COSA will be solely responsible for the operation of this pilot program, which may be terminated at any time.

    Any questions related to this approved pilot program should be directed to the President of COSA, Mr. Bill O'Donnell at bill@cosaonline.com.

     

    Additional information regarding new cobalt thresholds (April 21, 2017)

    Further to the Canadian Pari-Mutuel Agency's (CPMA) Industry Notice dated April 6, 2017, regarding the implementation of CPMA cobalt testing effective May 1, 2017, the CPMA has received questions about what this means from a practical perspective given that cobalt occurs naturally in the horse.

    As you may know, several provinces have been testing for cobalt for the past couple of years. The provincial testing of cobalt was in blood only, using a threshold of 50 nanograms per millilitre (ng/mL).

    The CPMA added cobalt to the list of quantitatively prohibited substances (section 2 of the schedule to the Pari-Mutuel Betting Supervision Regulations) in February of this year. After much research and collaboration with international regulators, it was determined that the thresholds for cobalt would be 25 ng/mL in blood and 100 ng/mL in urine. These levels are consistent with thresholds used in many other international jurisdictions.

    The CPMA's research indicates that vitamin supplements, when used alone and according to label directions, should not increase cobalt levels enough to cause a positive test. In addition, our research indicates that when horses were allowed free access to cobalt-containing salt blocks, there was little to no effect on the horse's cobalt levels.

    Cobalt levels may build up over time when given repeatedly, and its elimination from the horse can take an extended period of time. It is always good practice to take care and to read the list of ingredients when choosing products that are administered to horses. As with all medications and supplements, owners and trainers should discuss the use of cobalt supplements with their veterinarian.

    Should you have any questions or concerns, please contact CPMA by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Implementation of cobalt testing under the Canadian Pari-Mutuel Agency's Equine Drug Control Program (April 6, 2017)

    The Canadian Pari-Mutuel Agency (CPMA) would like to bring to the attention of the Canadian horse racing industry that as of February 22, 2017, cobalt was officially added to Section 2 of the Schedule to the Pari-Mutuel Betting Supervision Regulations. It should be noted that cobalt testing in Canada will move from provincial oversight to the CPMA under its official Equine Drug Control Program as of May 1, 2017.

    The CPMA would also like to advise the horse racing industry that the quantitative threshold for cobalt testing will decrease from 50 nanograms per millilitre (ng/mL) to 25 ng/mL in blood and that a new threshold of 100 ng/mL will be implemented in urine. These thresholds are published in the Pari-Mutuel Betting Supervision Regulations.

    The CPMA would like to remind industry participants to take care and to read the list of ingredients when choosing products that are administered to horses. As with all medications and supplements, owners and trainers should discuss the use of cobalt supplements with their veterinarian.

    Should you have any questions or concerns, please contact CPMA by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Update on items allowed in the retention area (March 28, 2017)

    Further to the Notice to Industry dated September 16, 2016, the Canadian Pari-Mutuel Agency (CPMA) has listened to feedback received concerning the number of buckets allowed in with a horse called to test and the prohibition of towels in the retention area.

    We acknowledge that due to current infrastructure at a small number of tracks, it can be difficult to both provide drinking water and water to cool a horse. Therefore, effective immediately, horsepersons will be able to once again bring two buckets into the retention area with a horse called to test.

    The CPMA has also received feedback regarding the decision to prohibit horsepersons from bringing towels into the retention area. CPMA does not have a concern with towels specifically, but rather with the substances that may be contained on the towel. Therefore, the CPMA has advised racecourse associations that they may, if they wish, stock clean towels within the retention area for use by horsepersons.

    The CPMA would like to thank those who shared their views and comments, and demonstrated their continued support for the operation of the CPMA's Equine Drug Control Program.

     

    Changes to urine collection container (March 24, 2017)

    Beginning May 1, 2017, the Canadian Pari-Mutuel Agency (CPMA) will be using a new urine collection container for the CPMA equine drug control program. The new container is a sterile, medical-grade 100 mL plastic container similar to what is used for human urine samples.

    Urine collection procedures will not change, and there will be no effect on CPMA Policy Paper P-006, Sample Residue Release.

    Horsepersons should note that effective May 1, 2017, official samples of urine will have a minimum required volume of 15 mL. If, after one hour, less than 15 mL of urine has been collected, any urine collected will be discarded and a blood sample drawn.

    Thank you for your continued support during the transition period.

    Should you have any questions or concerns regarding this change of approved paraphernalia, please contact CPMA by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Policy Paper P-010, Requests to collect official samples outside the retention area – Effective February 6, 2017

    Please be advised of the Canadian Pari-Mutuel Agency (CPMA) issuance of Policy P-010 respecting the Requests for Collection of Official Samples Outside the Retention Area.

    This paper will clarify the policy decision that official samples are not to be collected outside the retention area.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     
  • 2016
     

    Breakage rules for foreign race inter-track betting (October 19, 2016)

    The Canadian Pari-Mutuel Agency (CPMA) has recently reviewed the legislative provisions within the Criminal Code and the Pari-Mutuel Betting Supervision Regulations that pertain to the amounts associations may deduct and retain when participating in foreign-hosted pools.

    Subsection 204(6) of the Code allows an association to deduct and retain a percentage not exceeding the percentage prescribed by the Regulations (currently 35%), plus any odd cents over any multiple of five cents ('nickel breakage').

    Recognizing that some foreign jurisdictions use currencies and pay-out price calculations which do not accommodate nickel breakage, CPMA has sought an approach that would allow Canadians to participate in these popular pools.

    As such, the CPMA will accept applications to conduct foreign race inter-track betting (FRITB) using gross pool pricing where the breakage rules are different from nickel breakage, provided the total amount retained by the association for any individual pool does not exceed 35%, plus an amount equal to that which would result from applying nickel breakage when determining the amount payable for each dollar bet. This does not apply to authorizations that rely on net pool pricing, including all pari-mutuel pools hosted in Canada, as this pricing method accommodates nickel breakage.

    Because the use of foreign breakage rules is new to Canadian bettors, CPMA will require associations to clearly demonstrate how patrons participating in foreign betting pools will be informed of the applicable breakage rules, in advance of the betting.

    Applications for Foreign Race Inter-Track Betting should clearly indicate the breakage rules applied by the foreign pool host.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Revised list of items allowed in the retention area (September 16, 2016)

    In order to maintain an effective equine drug control program, the Canadian Pari-Mutuel Agency (CPMA) has revised the list of items allowed into the retention area. Please note that all items permitted into the retention area must leave with the horse.

    The new list of items is as follows:

    • Tack and equipment horse is wearing upon entry
    • Halter and leadshank
    • Empty bucket
    • Sponge, scraper
    • Horse blanket (cooler)
    • Equipment needed for sample collection, such as a twitch or blinkers
    • Dry leg wrap
    • Bandage cutters

    The revised list will have a full implementation date of October 1st, 2016.

    This new list balances the need for horsepersons to properly care for their horse with the responsibility to ensure a safe and controlled environment for the collection of equine samples. Consideration is also given to the fact that the horses are in the retention area for a short period of time, at most one hour.

    There are three main changes to the list of permitted items. Bandage cutters and leg wraps are now allowed. Leg wraps must be dry and clean upon entry; horsepersons are free to wet them in the retention area to apply "cold water" bandages. The type of leg wrap/bandage that is allowed has not been restricted.

    Towels will no longer be allowed in the retention area. Towels are tools that serve many purposes in a barn and consequently have the potential to be exposed to a variety of drugs and products, whether applied directly, or indirectly (for example, through horse saliva). Horsepersons will continue to have access to a scraper to dry their horse, a cooler of any weight (from fly sheet to wool cooler) to keep their horse's muscles from getting chilled and a sponge to clean their horse's head and nostrils.

    We understand that the revised list will require some adaptation by horsepersons. We would like to thank you for your ongoing cooperation to ensure that the equine drug control program remains effective and up to date.

     

    Exchange rate application when accepting fractional bets and participating in foreign hosted pari-mutuel pools (August 15, 2016)

    This is further to the September 22, 2011 Memorandum addressing Canadian associations accepting fractional bets when participating in foreign hosted pari-mutuel pools.

    In order to allow all Canadian associations to offer $.20 bets when participating in foreign-hosted pools, including those involving a Sportech pari-mutuel (Tote) system, Canadian Pari-Mutuel Agency (CPMA) will permit the exchange rate to be entered at the foreign pool host.

    Canadian associations continue to be responsible for establishing a procedure and for ensuring compliance with subsection 51(4) of the Pari-Mutuel Betting Supervision Regulations.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Human prescription medications as a potential route of drug exposure for racehorses (August 9, 2016)

    It has come to the Canadian Pari-Mutuel Agency's (CPMA) attention that the legitimate use of human prescription drugs by people handling racehorses can be a source of drug exposure for the horses that could, consequently, result in a positive drug test.

    Human urine is a proven source of drug exposure for racehorses. And although not proven at this time, exposure could also be to drugs directly, through human saliva or via unwashed hands.

    In the interest of accuracy and to reduce unintended positive drug tests, the CPMA therefore strongly discourages people from urinating or spitting in horse stalls, and recommends that all people who handle racehorses wash their hands immediately after contact with, or consumption of, medications, and avoid bringing human prescription medications into barns whenever possible.

     

    Guidelines for requesting changes to the RCI Model Rules (May 3, 2016)

    This memo provides direction to Canadian race-course associations interested in seeking pool rule changes to the Association of Racing Commissioners Internationals' (ARCI) Model Rules, which are incorporated by reference in section 143 of the Pari-Mutuel Betting Supervision Regulations (the Regulations).

    Beyond the pools described in the Regulations, Canadian race-course associations may also apply to operate pools described in the RCI Model Rules (for example, Pick (n) Pools, Superfecta, Pentafecta), provided they comply with the Criminal Code and the Regulations.

    Should an association wish to add a new pool or amend an existing one, the association must submit a request in writing to the Canadian Pari-Mutuel Agency (CPMA) describing the desired amendment. CPMA will then work with the association to draft wording describing the rule change. As a member of the ARCI, the CPMA will submit a petition to the ARCI for its consideration and adoption into the RCI Model Rules.

    Once the rule change is adopted by the ARCI, Canadian race-course associations may make an amended application to use the pool rule under their betting permit or applicable authorization (for example, Inter-track betting, separate pool betting or foreign race inter-track betting).

    RCI Model Rules are available under Acts and Regulations - Canadian Pari-Mutuel Agency.

     

    Reminder: Full implementation of the Elimination Guidelines 2016 coming into force May 1, 2016

    This is further to previous Industry Notifications respecting the implementation of the 2016 Elimination Guidelines.

    We would like to remind owners and trainers that full implementation of the 2016 Elimination Guidelines will take effect on May 1, 2016, and that testing will be consistent with these guidelines. Changes from the 2011 Schedule of Drugs can be found in CPMA notices to industry dated January 20 and March 3, 2016.

    Particular attention needs to be paid to those drugs that were removed from the 2011 Schedule of Drugs (see notice to industry dated March 3, 2016 for the full list of removed drugs). Some of these drugs, such as flumethasone, are no longer available in an approved veterinary formulation and are now only available as a compounded product. Testing will continue for removed drugs.

    We would also like to remind owners and trainers about the CPMA's position with regards to the use of compounded medications. Previously established elimination guidelines should not be applied to compounded products. Positive certificates of analysis resulting from administration of compounded medication remain the responsibility of the owner and trainer.

    For further information, contact the CPMA at 1-800-268-8835, or by email at: cpmawebacpm@agr.gc.ca

     

    Clarification on the changes in the Canadian Pari-Mutuel Agency's Elimination Guidelines 2016 booklet – March 3, 2016

    As mentioned in the CPMA memorandum of January 20th, 2016, the recently released Elimination Guidelines 2016 booklet contains several modifications from previous editions of the booklet. The intent of this memorandum is to clarify what the new changes mean to racing industry participants. A summary of these changes is presented in the attached table.

    Notably, CPMA no longer provides elimination guidelines for some substances previously covered in the booklet. Testing of official samples for the presence of these substances will however continue, as they remain on the List of Drugs prohibited by the Pari-Mutuel Betting Supervision Regulations.

    Other changes include longer elimination times and the removal of elimination guidelines for doses and routes of some substances contained in previous editions of the booklet. These guidelines can no longer be relied upon for avoiding a positive test.

    The elimination guidelines in the 2016 booklet are the current guidelines and stakeholders are encouraged to familiarize themselves with all the changes in the new publication (booklet).

    CPMA continues to recommend that owners, trainers or any person in charge of or having care of a race horse consult their own veterinarian for advice and guidance in the use of all drugs and medications in their horses.

    The CPMA's Elimination Guidelines 2016 booklet replaces all previous editions of the CPMA's Schedule of Drugs.

    Elimination Guidelines 2016 - summary of changes and what they mean

    Substances completely removed from the booklet: What does this mean to owners, trainers, veterinarians, etc.?
    • Azaperone
    • Boldenone
    • Flumethasone
    • Isoxsuprine
    • Nandrolone
    • Oxyphenbutazone
    • Promazine
    • Stanozolol
    • Testosterone
    • Thiosalicylic Acid
    • Testing of official samples for these substances will continue.
    • No elimination guidelines will be provided.
    • Elimination guidelines for doses and routes contained in previous editions of the booklet can no longer be relied upon for avoiding a positive test
    Substances with some doses and routes removed from booklet: What does this mean to owners, trainers, veterinarians, etc.?
    • Betamethasone
    • Butorphanol
    • Clenbuterol
    • Cromoglycate
    • DexamethasoneIsoflupredone
    • Methylprednisolone
    • Prednisolone
    • Prednisone
    • Triamcinolone acetonide
    • Xylazine
    • Testing of official samples for these substances will continue.
    • The elimination guidelines in the 2016 booklet are the current guidelines.
    • Elimination guidelines for doses and routes contained in previous editions of the booklet can no longer be relied upon for avoiding a positive test
    Substances with extended elimination guideline (some doses and routes): What does this mean to owners, trainers, veterinarians, etc.?
    • Betamethasone
    • Butorphanol
    • Clenbuterol
    • Cromoglycate
    • DexamethasoneIsoflupredone
    • Methylprednisolone
    • Prednisolone
    • Prednisone
    • Triamcinolone acetonide
    • Xylazine
    • Testing of official samples for these substances will continue.
    • The elimination guidelines in the 2016 booklet are the current guidelines.
    • Elimination guidelines for doses and routes contained in previous editions of the booklet can no longer be relied upon for avoiding a positive test
    Substances with extended elimination guideline (some doses and routes): What does this mean to owners, trainers, veterinarians, etc.?
    • Betamethasone
    • Clenbuterol
    • Dexamethasone
    • Methylprednisolone
    • Prednisolone
    • Prednisone
    • Triamcinolone acetonide
    • Testing of official samples for these substances will continue.
    • The elimination guidelines in the 2016 booklet are the current guidelines.
    • Elimination guidelines for doses and routes contained in previous editions of the booklet can no longer be relied upon for avoiding a positive test
    Substances with minor changes: What does this mean to owners, trainers, veterinarians, etc.?
    • Acetaminophen
    • Furosemide
    • Pentazocine
    • Testing of official samples for these substances will continue.
    • The elimination guidelines in the 2016 booklet are the current guidelines.
    • Changes to the booklet will have no effect on how these substances are currently tested.
  • 2015
     

    Ractopamine in feedstuffs clarification (September 1, 2015)

    This is further to the notices to industry issued by the Canadian Pari-Mutuel Agency (CPMA) regarding the use of ractopamine in feedstuffs and, more specifically, the August 21st 2015 update respecting the Canadian Food Inspection Agency's (CFIA) Canadian Ractopamine Free Certification Program and the identification of Type A commercial feed facilities.

    The CPMA wishes to clarify that the CFIA's Type A commercial feed facility designation is limited to the drug ractopamine and means that the feed facility does not have ractopamine on its premises. However, it is important to note that this designation does not prevent such a facility from having other drugs on its premises that may be prohibited under the Canadian Pari-Mutuel Betting Supervisions Regulations (the Regulations).

    In addition, Type A commercial feed facilities are not the only feed facilities that do not use ractopamine. There are other feed mills that do not have this designation that may be drug free and therefore would not have ractopamine on their premises.

    The CPMA does not endorse any particular type of facility and does not provide any type of guarantee with respect to any feed supplier, its products or its facilities. It remains the responsibility of owners and trainers to ensure that the horse feed and supplements they use are free from substances that may result in a positive test under the Regulations.

     

    Ractopamine in feedstuffs update (August 21, 2015)

    This memo is further to our notices to industry on February 14 and November 3, 2014, on the subject of ractopamine in feedstuffs wherein we reminded race horse owners and trainers that it remains their responsibility to obtain horse feed and supplements that are free from substances that may trigger a positive test such as ractopamine.

    Please be advised that the Canadian Food Inspection Agency (CFIA) has published a list of commercial feed facilities enrolled in the Canadian Ractopamine-Free Pork Certification Program. Race horse trainers and owners may wish to obtain their feed from facilities that have been designated as Type A which are those commercial facilities (feed mills and feed retail outlets) that manufacture, handle and/or distribute only feeds that do not contain ractopamine. They have never manufactured and/or distributed mixed feeds containing ractopamine (including trucking) or have followed the protocols established by CFIA to clean-up their facility.

    The list, along with information regarding the Canadian Ractopamine-Free Pork Certification Program is available from the Canadian Food inspection Agency. Please note that this list is being updated as new facilities enroll.

    Should you have any questions, please contact the CPMA at 1-800-268-8835, or by email at: aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Certificates of positive analysis for oxilofrine (July 8, 2015)

    Oxilofrine is an amphetamine type stimulant. Its use has been reported in human and equine athletes. The Association of Racing Commissioners International (ARCI) categorizes it as a Class 2, Penalty A substance. The Pari-Mutuel Betting Supervision Regulations do not permit the use of oxilofrine.

    Recently conducted target testing for the drug oxilofrine resulted in four certificates of positive analysis being issued in the province of Ontario. Consequently, the CPMA carried out an investigation. A preliminary explanation for these positives may be the result of horsemen using products containing ephedrine.

    CPMA is conducting further research on oxilofrine and ephedrine, and will advise the industry of its findings upon completion of these studies.

    In the meantime, measures have been instituted to ensure that a positive test will not result when products containing ephedrine are used in a manner consistent with the elimination guidelines provided in the CPMA's 2011 Schedule of Drugs booklet.

  • 2014
     

    Ractopamine in feedstuffs update (November 3, 2014)

    This memo is further to our notice to industry on February 14, 2014 on the subject of ractopamine in feedstuffs wherein we reminded race horse owners and trainers that it remains their responsibility to obtain horse feed and supplements that are free from substances that may trigger a positive test.

    Since we issued that memo, there have been 27 additional positive drug tests for ractopamine in all racing jurisdictions in Canada except the Atlantic provinces with the majority coming from Alberta and Ontario.

    The CPMA has initiated discussions with horseperson's groups across the country to discuss ways of reducing the risk of positive ractopamine drug tests.

    One suggestion is that horseperson's groups take a proactive approach to assisting their membership locate feed facilities that do not produce feed containing ractopamine and having their feed manufacturers sign a letter of guarantee stating that they do not use ractopamine in the manufacturing of feed, store ractopamine on their premises or transport any mixed feed containing ractopamine.

    The Canadian Food Inspection Agency (CFIA) has been working with the swine and poultry sectors to develop a program that supports export to markets that require the CFIA to certify that products, exported from Canada, originate from stock that has never been fed and/or exposed to ractopamine hydrochloride. These Ractopamine-Free Certification Programs describe two types of commercial feed mills; Type A and Type B. Type A mills are those that manufacture, handle and/or distribute only feeds that do not contain ractopamine. Type B mills manufacture, handle and/or distribute feed containing ractopamine and feed that does not contain ractopamine. Type B mills are required to implement Standard Operating Procedures (SOPs) for the prevention of ractopamine cross contamination for feed being manufactured under this program. When these new Programs are published on the CFIA web-site, a list of commercial feed mills enrolled in these Programs will also be available. This list may be used to identify the Type A facilities in your area.

    According to the CFIA's Medication Sequencing Guideline for Management of Drug Carryover, feeds for horses may not directly follow feeds containing ractopamine. Horse feeds that contain ractopamine above the limit of detection are non-compliant. However, the current level of detection is fairly high so in some cases when the horse feed conforms with this allowable limit, the feed may contain enough ractopamine to cause a positive result in the CPMA's drug testing program.

    The following links to the CFIA website provide owners and trainers with information regarding ractopamine and feedstuffs:

    Should you have any questions with respect to the contents of the memorandum, please contact the CPMA at 1-800-268-8835, or email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Compounded medications (May 29, 2014)

    The compounding of drugs is an accepted veterinary practice and when properly prescribed, created and administered, they can be an appropriate and effective treatment for your horse.

    Compounded drugs are commonly used when a licensed product is not available or when a different strength or form (for example, compounded paste instead of a tablet) are required.

    Compounding involves the combining or mixing together of two or more ingredients (of which at least one is a drug or pharmacologically active component) to create a final product in an appropriate form for dosing.

    When treating race horses with compounded medications it may be wise to add extra time to the published elimination guidelines. Owners, trainers or any person in charge or having care of a race horse are strongly advised to consult their own veterinarian for advice and guidance in the use of all drugs.

    Positive certificates of analysis resulting from administrations of compounded medication remain the responsibility of the trainer.

    Should you have any questions or comments with respect to this notice, please contact Dr. Adam Chambers Bachelor of Veterinary Medicine and Science (BVMS), at Adam.Chambers@agr.gc.ca.

     

    Ractopamine in feedstuffs (February 14, 2014)

    This memo is with respect to several recent positive drug tests that may have been the result of prohibited substances in feedstuffs. This is a reminder to owners and trainers that it remains their responsibility to obtain horse feed and supplements that are free from substances that may trigger a positive test.

    One of these prohibited substances is ractopamine, which is used to promote weight gain and feed efficiency and is licensed in Canada for use in beef cattle, pigs and turkeys.

    Following several positive tests in Ontario, the Ontario Racing Commission undertook an investigation that found ractopamine in batches of horse feed. Similar findings were heard from Alberta and Quebec. Upon receipt of this information, The Canadian Pari-Mutuel Agency (CPMA) initiated discussions with the Canadian Food Inspection Agency (CFIA) wherein it was determined that the CFIA has set allowable limits of ractopamine to be present in feed. However, even if horse feed passes these allowable limit tests, the feed may contain enough ractopamine to cause a positive result in the CPMA's drug testing program.

    CFIA also advised that it has a program for feed mills that minimizes the likelihood of ractopamine being found in feed for animals destined for international markets that do not allow any amounts of ractopamine in exported meat. The threat of an unintended positive test result to Canadian horsepeople may be minimized in several ways including but not limited to obtaining feed from manufacturers certifying that ractopamine is not used in feed produced at their facility.

    It is suggested that owner and trainers make agreements with feed suppliers that their feed come from sources that minimize the risks of contamination. As mentioned at the outset of this memo, positive tests remain the owner's/trainer's responsibility.

    Medicating ingredients permitted in Canadian feeds that may cause a positive test in the CPMA's drug testing program include but are not necessarily limited to: ractopamine, zilpaterol, procaine penicillin and levamisole.

    The following links to the CFIA website provide owners and trainers with information regarding ractopamine and feedstuffs.

    Should you have any questions with respect to the contents of the memorandum, please do not hesitate to contact Lydia Brooks, Manager, Research and Analysis (613-949-0745 or lydia.brooks@agr.gc.ca) or Dr. Adam Chambers (905-648-3033 or adam.chambers@canada.ca).

  • 2012
     

    Ethanol testing (January 16, 2012)

    As part of the CPMA's ongoing research program we examine many products for metabolism and elimination profiles in the horse with the aim of improving detection and confirmation of schedule drugs.

    As a result of a recent research, methods have been improved such that confirmable levels of Ethanol and/or its metabolites can now be identified in official samples. CPMA evaluates all of the information available and makes decisions related to advance notification of changes on a case by case basis.

    Ethanol, a central nervous system depressant is widely available in many forms and is found in numerous products including but not limited to beverages, topical disinfectants, tinctures, homeopathic remedies, topical liniments and leg rubs. Inappropriate use of ethanol may result in psychoactive and other effects. Typically it can be absorbed after oral, intravenous and topical administration.

    This notice is to remind industry participants to take care and to read the label of ingredients when choosing products that are administered to horses.

    As of February 13, 2012, official samples will be tested for ethanol, and any confirmed detection will be called positive according to Section 165 of the Regulations.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

  • 2011
     

    Canadian fractional bets - foreign race inter-track betting - (September 22, 2011)

    This is further to my August 25, 2011 Memorandum with respect to permitting foreign guest associations to offer fractional bets of their native currency.

    At a recent Racetracks of Canada teleconference, the CPMA was asked if Canadian associations could offer bets in amounts less than $1 (Canadian) increments when betting into foreign hosted pari-mutuel pools.

    In response, the CPMA confirms that the same requirement applies to all fractional bets offered to Canadian bettors whether the bets are merged with domestic or foreign pari-mutuel pools. That is, bets may be made in multiples of $0.20 (Canadian). This particular "multiple" is specified in order to comply with subsection 204(6) of the Criminal Code, relating to "breakage" (that is, minimum payout of five cents for each winning dollar).

    Further to this legislative requirement, there may be additional constraints affecting an association's ability to merge fractional bets with the foreign pool host, including foreign pari-mutuel rules or other contractual requirements with foreign associations concerning wagers.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    Policy Paper P-005, Non-official equine related samples – (February 15, 2011)

    Please be advised of the CPMA issuance of Policy Paper P-005, Non-official equine related samples.

    This paper will clarify policies regarding the submission of non-official samples for analysis by the CPMA's Official Laboratory. It also describes responsibilities regarding payment for the shipping and analysis, and controls regarding the release of the results of analysis of those samples. As well, the paper confirms the current practice of prohibiting the shipping of non-official samples within the same container as Official Samples.

    Only equine samples submitted by PRBs may be analyzed at the Official Laboratory. Generally, there are two types of non-official samples typically submitted for analysis; those collected from a horse that has participated in a race upon which there is no pari-mutuel betting (for example, qualifying and or non-betting stakes races), and those which have been collected in relation to an investigation.

    If a PRB wishes to have 'non-wagering' samples or samples collected in relation to an ongoing investigation analyzed by the Official Laboratory or to have samples collected in relation to an ongoing investigation analyzed by the Official Laboratory, they should contact the CPMA, in advance.

    In closing, if you have any questions or require clarification, please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     

    P-003, Approval of Canadian Associations' Pari-Mutuel systems located outside of Canada – (February 10, 2011)

    Please be advised of the CPMA Policy P-003, Approval of Canadian Associations' Pari-Mutuel Systems Located Outside of Canada.

    Should you have any questions please contact the CPMA at 1-800-268-8835, or by email at aafc.cpmawebacpm.aac@agr.gc.ca.

     
Date modified: